Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01089-18. doi: 10.1128/AAC.01089-18. Print 2018 Nov.

PMID:
30126953
2.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
3.

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY; Protocol 005 Team.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):456-63.

4.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa.

Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

5.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
6.

Effects of omeprazole on plasma levels of raltegravir.

Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, Hanley WD, Jin B, Harvey CM, Breidinger SA, Azrolan N, Farmer HF Jr, Isaacs RD, Chodakewitz JA, Stone JA, Wagner JA.

Clin Infect Dis. 2009 Feb 15;48(4):489-92. doi: 10.1086/596503.

PMID:
19143531
7.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

8.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

9.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
10.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team.

Lancet. 2007 Apr 14;369(9569):1261-1269. doi: 10.1016/S0140-6736(07)60597-2.

PMID:
17434401
11.

Ertapenem therapy for community-acquired pneumonia in the elderly.

Woods GL, Isaacs RD, McCarroll KA, Friedland IR.

J Am Geriatr Soc. 2003 Nov;51(11):1526-32.

PMID:
14687380
12.

Ertapenem, the first of a new group of carbapenems.

Shah PM, Isaacs RD.

J Antimicrob Chemother. 2003 Oct;52(4):538-42. Epub 2003 Sep 1. Review. No abstract available.

PMID:
12951340
13.

Borrelia burgdorferi bind to epithelial cell proteoglycans.

Isaacs RD.

J Clin Invest. 1994 Feb;93(2):809-19.

14.

Lipoproteins of Borrelia burgdorferi and Treponema pallidum activate cachectin/tumor necrosis factor synthesis. Analysis using a CAT reporter construct.

Radolf JD, Norgard MV, Brandt ME, Isaacs RD, Thompson PA, Beutler B.

J Immunol. 1991 Sep 15;147(6):1968-74.

PMID:
1890308
16.

Molecular cloning and DNA sequence analysis of the 37-kilodalton endoflagellar sheath protein gene of Treponema pallidum.

Isaacs RD, Hanke JH, Guzman-Verduzco LM, Newport G, Agabian N, Norgard MV, Lukehart SA, Radolf JD.

Infect Immun. 1989 Nov;57(11):3403-11.

17.

Short course chemotherapy for meningococcal meningitis.

Isaacs RD, Howden CW, Lang WR, Ellis-Pegler RB.

Aust N Z J Med. 1988 Aug;18(5):731-2. No abstract available.

PMID:
3245827
18.

Wound infection with aerogenic Aeromonas strains: a review of twenty-seven cases.

Isaacs RD, Paviour SD, Bunker DE, Lang SD.

Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):355-60. Review.

PMID:
3137035
19.

Long-term cytotoxicity of orthodontic direct-bonding adhesives.

Tell RT, Sydiskis RJ, Isaacs RD, Davidson WM.

Am J Orthod Dentofacial Orthop. 1988 May;93(5):419-22.

PMID:
3284332
20.

Successful treatment of Morganella morganii meningitis with pefloxacin mesylate.

Isaacs RD, Ellis-Pegler RB.

J Antimicrob Chemother. 1987 Nov;20(5):769-70. No abstract available.

PMID:
3480886
21.

Diabetic patient discharges from Middlemore Hospital in 1983.

Isaacs RD, Scott DJ.

N Z Med J. 1987 Oct 14;100(833):629-31.

PMID:
3452113
22.

Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations.

Isaacs RD, Nicholson GI, Holdaway IM.

Thorax. 1987 Jul;42(7):555-6. No abstract available.

23.

Osteomyelitis complicating a closed fracture.

Folberg C, Hardy AE, Isaacs RD, Ellis-Pegler RB.

N Z Med J. 1987 Jun 24;100(826):392-3. No abstract available.

PMID:
3451117
24.

Plasmodium falciparum RI resistance to quinine and sulphadoxine-pyrimethamine in the Solomon Islands.

Isaacs RD, Ellis-Pegler RB.

Med J Aust. 1987 Apr 20;146(8):449-50. No abstract available.

PMID:
3302637
25.

Massive haemoptysis as a late consequence of pulmonary irradiation.

Isaacs RD, Wattie WJ, Wells AU, Rea HH, Bai TR.

Thorax. 1987 Jan;42(1):77-8. No abstract available.

26.

Cystic hydatid disease in Auckland, New Zealand, 1967-1982.

Isaacs RD, Beeching NJ, Ellis-Pegler RB.

Trans R Soc Trop Med Hyg. 1987;81(5):794-8.

PMID:
3449998
27.

Severe falciparum malaria.

Isaacs RD, Ellis-Pegler RB.

N Z Med J. 1986 Sep 10;99(809):683. No abstract available.

PMID:
3531930
28.

Necrotizing pneumonia in bacteraemic pneumococcal infection.

Isaacs RD.

Br J Dis Chest. 1986 Jul;80(3):295-6.

PMID:
3790423
29.

A prospective study of routine dipstick urinalysis in acute medical admissions to Middlemore Hospital.

Isaacs RD.

N Z Med J. 1986 Jun 25;99(804):467. No abstract available.

PMID:
3461375
30.

Idiopathic giant cell myocarditis: case report.

Isaacs RD, Roche AH, Smeeton WM, Ali MR, Croxson MC.

N Z Med J. 1986 May 28;99(802):360-1.

PMID:
3022212

Supplemental Content

Loading ...
Support Center